Patents by Inventor Emmanuel Heron

Emmanuel Heron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of hydroxycarbamide for preventing retinal nonperfusion
    Patent number: 10617658
    Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: April 14, 2020
    Assignees: CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE QUINZE-VINGTS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICAL (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTES
    Inventors: Yves Colin, Jean-Francois Girmens, Olivier Hermine, Emmanuel Heron, Michel Paques
  • USE OF HYDROXYCARBAMIDE FOR PREVENTING RETINAL NONPERFUSION
    Publication number: 20180221313
    Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.
    Type: Application
    Filed: August 8, 2016
    Publication date: August 9, 2018
    Applicant: Centre National De La Recherche Scientifique (CNRS)
    Inventors: Yves COLIN, Jean-Francois GIRMENS, Olivier HERMINE, Emmanuel HERON, Michel PAQUES
  • Methods and pharmaceutical compositions for treatment of retinal occlusion
    Patent number: 9463217
    Abstract: The present invention relates to methods and compositions for the treatment of retinal vein occlusion.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: October 11, 2016
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes—Paris V, Université Paris Diderot—Paris VII, Université des Antilles et de la Guyane, Institut National de la Transfusion Sanguinge (INTS), Assistance Publique—Hôpitaux de Paris, CHN OPHTALMOLOGIE QUINZE-VINGTS
    Inventors: Yves Colin Aronovicz, Olivier Hermine, Marie-Paule Wautier, Jean-Luc Wautier, Emmanuel Heron